Navigation Links
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Date:3/23/2010

Robert L. Kirkman, M.D., President and CEO of Oncothyreon. "We understand that Merck Serono is working closely with the FDA, other regulatory agencies and the patient's physicians to evaluate the implications of this adverse reaction and to determine an appropriate course of action."

The exploratory trial in multiple myeloma is designed to investigate the mechanism of action of Stimuvax and the effect of cyclophosphamide on regulatory T cells, which may affect the response to the therapeutic vaccine. The adverse event occurred in a patient receiving a more intensive regimen of low-dose cyclophosphamide than is utilized in the Phase 3 program. The patient developed an encephalitis, or inflammation of the brain. No other events of this kind have been reported in other trials of Stimuvax to date.

Conference Call Information

Oncothyreon will host a conference call and webcast today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. To participate in the call by telephone, please dial 877-280-7291 (United States) or 707-287-9361 (International). In addition, the call is being webcast live and can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
2. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
3. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
4. Oncothyreon announces webcast of third quarter 2009 financial results conference call
5. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
6. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
7. Oncothyreon reports second quarter 2009 financial results
8. Oncothyreon announces closing of $15.0 million registered direct financing
9. Oncothyreon announces webcast of second quarter 2009 financial results conference call
10. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
11. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Potential Efficacy in Huntington,s Disease Already Demonstrated, ... Pharmaceuticals,Corp. ("Raptor" or the "Company") (OTC Bulletin ... and Drug Administration ("FDA") has granted,orphan drug ... of Huntington,s disease ("HD"). Cysteamine is currently ...
... for Early Identification of High Risk Patients Early ... Intervention Can Help Prevent Disease Progression, SAN FRANCISCO, ... 68th Scientific Sessions of the American Diabetes Association,(ADA) that ... Diabetes,Risk Test, a first-of-its-kind predictive tool that delivers an ...
... June 6 Bioheart, Inc. (Nasdaq:,BHRT) will host its ... at Chispa Restaurant, located at 11500 NW 41st Street ... EASTERN., Interested parties may listen to the Bioheart, ... (domestic) or (706) 643-0580,(international). To listen to the Annual ...
Cached Biology Technology:Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 2Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 3Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 4Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 5Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 2Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 3Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 4Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008 2
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... research team led by a Michigan State University professor has discovered ... help treat one of the disease,s most common and potentially blindness-causing ... to blood vessels in the retina that affects up to 80 ... in damage to the nerves found in bone marrow that leads ...
... report that Helicobacter pylori , the only bacterium ... human stomach, directly activates an enzyme in host cells ... including gastric cancer. Chronic infection with H. ... forms of gastric cancer, but researchers have not yet ...
... a growing number of fast food and chain restaurants display ... a study suggests some of this information may be unreliable. ... 18 side dishes and entrees from national sit-down chain restaurants, ... and 10 frozen meals purchased from supermarkets. They compared their ...
Cached Biology News:MSU researcher links diabetic complication, nerve damage in bone marrow 2Team finds link between stomach-cancer bug and cancer-promoting factor 2Team finds link between stomach-cancer bug and cancer-promoting factor 3Study examines calorie information from restaurants, packaged foods 2
... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
... bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. HYGROSCOPIC. ... CHAPSO. Has reduced electrostatic interactions that do ... DEAE-cellulose. Aggregation number: 8-16. Purity: ≥95% ... O. Aggregation number 8 - 16, CMC ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Biology Products: